The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Open accessAbstract
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflammation, and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in non-bone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, HSC mediators besides RSPO3, such as HGF, but possibly also neurotrophin-319 or epiregulin60 may be involved in additional aspects of HSC–hepatocyte cross-talk and—together with ECs29,59—collaboratively control hepatocyte health and functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [60]
In the citing paper
“These pro-inflammatory mediators not only promote the development of CLD but also set the stage for the development of HCC13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“However, a failing gut barrier and alterations of the gut microbiota in chronic liver disease (CLD) contribute to chronic inflammation and the progression of liver diseases12, and thereby increase risk for the development of hepatocellular carcinoma (HCC) as the final stage of the disease process 13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Nonetheless, the bacterial microbiota has an important role in promoting HCC in the setting of liver fibrosis, as demonstrated by reduced HCC formation in TLR4-deficient, germ-free and antibiotic-treated mice in a diethylnitrosamine (DEN) plus CCl4 model of HCC13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“It has become apparent that the endogenous commensal microbiota provides hepatoprotective signals and that complete absence of the gut microbiota results in increased liver injury — probably owing to an absence of TLR4-mediated activation of anti-apoptotic NF-κB signalling — and a subsequent increase in liver fibrosis, as demonstrated in several models13,75,76.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Consistent with previous studies71–73, treatment with nonabsorbable antibiotics resulted in a strong reduction of fibrosis despite increased liver injury13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Experiments in bone-marrow-chimeric mice demonstrated that TLR4 expressed on liver-resident cells (which include hepatocytes, HSCs and Kupffer cells) is responsible for promotion of fibrogenesis and hepatocarcinogenesis13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, epiregulin-deficient mice displayed reduced hepatocarcinogenesis when treated with DEN+CCl413.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Conversely, inhibition of TLR4 signalling suppresses liver inflammation, fibrosis and HCC formation in mice and rats13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, chronic infusion of low-dose LPS via osmotic pumps promotes HCC development in mice13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“As such, HCC development induced by the combination of DEN and CCl4 was attenuated in gut-sterilized and germ-free mice compared with their specific pathogen-free counterparts13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, expression of the apoptosis marker cleaved caspase 3 in TLR4-deficient and gut-sterilized mice is inversely correlated with the formation of tumours13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“In HSCs, TLR4 activation leads to an NF-κB-mediated upregulation of the hepatomitogen epiregulin13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Continuous gut sterilization by a cocktail of oral antibiotics, consisting of ampicillin, neomycin, metronidazole and vancomycin, effectively reduced the number and size of HCC induced by DEN+CCl4 or DMBA+HFD in mice13,15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, rifaximin reduces HCC development in the DEN–CCl4 model of HCC, albeit less efficiently than the quadruple antibiotics cocktail described above13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, administration of antibiotics at late stages of carcinogenesis, when microscopic tumours already existed, was more efficient at reducing HCC in mice than administration at earlier stages13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“supported by a large number of studies preclinical studies showing a drastic (≈80%) reduction of HCC development in murine models13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Several studies have shown a key role for the TLR4 pathway as a mediator of the disease-promoting effects of the gut–liver axis in CLD and hepatocarcinogenesis13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Wang, C.-Y., Mayo, M., Korneluk, R., Goeddel, D., & Baldwin, A. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,950
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,587
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben‐Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,423
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Toyoda, 1995, Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes, J. Biol. Chem., 270, 7495
Cited by
Sorted by citations
Items 301–400 of 999
The insights of Let‐7 miRNAs in oncogenesis and stem cell potency
Sun, X., Liu, J., Xu, C., Tang, S., & Ren, H. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12861 · Cited by 78
Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
Jiang, X., Zheng, J., Zhang, S., Wang, B., Wu, C., & Guo, X. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00361 · Cited by 80
Wang, J., Zhu, G., Sun, C., Xiong, K., Yao, T., Su, Y., & Fang, H. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01417-x · Cited by 77
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis
Iida, N., Mizukoshi, E., Yamashita, T., Yutani, M., Seishima, J., Wang, Z., Arai, K., Okada, H., Yamashita, T., Sakai, Y., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00251-3 · Cited by 80
Thiele, M. S., Albillos, A., Abazi, R., Wiest, R., Gluud, L. L., & Krag, A. A. (2015) · Liver International · doi:10.1111/liv.12782 · Cited by 77
Intestinal microbiota in liver disease
Haque, T., & Barritt, A. S. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.02.004 · Cited by 76
Hackstein, C.-P., Assmus, L. M., Welz, M., Klein, S., Schwandt, T., Schultze, J. L., Förster, I., Gondorf, F., Beyer, M., Kroy, D. C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311224 · Cited by 83
Vanni, E., & Bugianesi, E. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.001 · Cited by 79
Pathogenesis of hepatocellular carcinoma according to aetiology
Nault, J. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.08.006 · Cited by 75
Lurje, I., Werner, W., Mohr, R. U., Roderburg, C., Tacke, F., & Hammerich, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650486 · Cited by 79
Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., & Miele, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126485 · Cited by 77
Kang, Y., Cai, Y., & Yang, Y. X. (2021) · Liver Cancer · doi:10.1159/000521358 · Cited by 78
Targeting gut flora to prevent progression of hepatocellular carcinoma
Darnaud, M., Faivre, J., & Moniaux, N. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.019 · Cited by 76
Ericsson, A. C., Personett, A. R., Turner, G., Dorfmeyer, R. A., & Franklin, C. L. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00196 · Cited by 77
Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either
Hartmann, P., Chu, H., Duan, Y., & Schnabl, B. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00370.2018 · Cited by 74
Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti‐tumor immunity
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F., & Makowski, L. (2020) · Immunological Reviews · doi:10.1111/imr.12856 · Cited by 75
Ohtani, N. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0457-1 · Cited by 76
p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release
Yan, H., Wu, H., Zhang, H., Ashton, C., Tong, C., Wu, H., Qian, Q., Wang, H.-Y., & Ying, Q. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.029 · Cited by 76
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Zhou, D., Luan, J., Huang, C., & Li, J. (2020) · Gut and Liver · doi:10.5009/gnl20223 · Cited by 74
Huang, Y., Yang, X. F., Meng, Y., Shao, C., Liao, J., Li, F., Li, R., Jing, Y., & Huang, A. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00683-5 · Cited by 76
The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
Mehal, W. Z. (2014) · Digestive Diseases · doi:10.1159/000360495 · Cited by 77
Obesity and the liver: nonalcoholic fatty liver disease
Koppe, S. (2014) · Translational research · doi:10.1016/j.trsl.2014.06.008 · Cited by 74
Kawai, H., Osawa, Y., Matsuda, M., Tsunoda, T., Yanagida, K., Hishikawa, D., Okawara, M., Sakamoto, Y., Shimagaki, T., Tsutsui, Y., et al. (2022) · Hepatology · doi:10.1002/hep.32256 · Cited by 72
Garcia‐Vilas, J. A., & Medina, M. Á. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3695 · Cited by 72
Gut microbiota: A new piece in understanding hepatocarcinogenesis
Zhou, A., Tang, L., Zeng, S., Lei, Y., Yang, S., & Tang, B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.002 · Cited by 76
Riedel, S., Pheiffer, C., Johnson, R., Louw, J., & Muller, C. J. F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.833544 · Cited by 78
Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation
Maehara, N., Arai, S., Mori, M., Iwamura, Y., Kurokawa, J., Kai, T., Kusunoki, S., Taniguchi, K., Ikeda, K., Ohara, O., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.058 · Cited by 74
Gut Microbiota and Hepatocellular Carcinoma
Tao, X., Wang, N., & Qin, W. (2015) · Gastrointestinal Tumors · doi:10.1159/000380895 · Cited by 72
Chen, J., Wei, Y., He, J., Cui, G., Zhu, Y., Lu, C., Ding, Y., Xue, R., Bai, L., Uede, T., et al. (2014) · Scientific Reports · doi:10.1038/srep07259 · Cited by 71
TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
Li, S., Sun, R., Chen, Y., Wei, H., & Tian, Z. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2371 · Cited by 71
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Espinosa-Sánchez, A., Suárez-Martínez, E., Sánchez-Díaz, L., & Carnero, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01533 · Cited by 77
Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
Longhi, G., van Sinderen, D., Ventura, M., & Turroni, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.575072 · Cited by 72
Obesity and Cancer: A Gut Microbial Connection
Ohtani, N., Yoshimoto, S., & Hara, E. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3501 · Cited by 71
Anatomical localization of commensal bacteria in immune cell homeostasis and disease
Fung, T. C., Artis, D., & Sonnenberg, G. F. (2014) · Immunological Reviews · doi:10.1111/imr.12186 · Cited by 75
Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame
Ramadori, P., Cubero, F. J., Liedtke, C., Trautwein, C., & Nevzorova, Y. A. (2017) · Cancers · doi:10.3390/cancers9100130 · Cited by 70
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 70
Role of the microbiome in non-gastrointestinal cancers
Pevsner‐Fischer, M., Tuganbaev, T., Meijer, M. T., Zhang, S., Zeng, Z., Chen, M., & Elinav, E. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i2.200 · Cited by 72
Chen, K., Ma, J., Jia, X., Ai, W., Ma, Z., & Pan, Q. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.005 · Cited by 72
Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
Jílková, Z. M., Kurma, K., & Decaens, T. (2019) · Cancers · doi:10.3390/cancers11101487 · Cited by 78
Ponziani, F. R., Nicoletti, A., Gasbarrini, A., & Pompili, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919848184 · Cited by 70
Vancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota
Singh, V., Yeoh, B. S., Abokor, A. A., Golonka, R. M., Tian, Y., Patterson, A. D., Joe, B., Heikenwälder, M. F., & Vijay–Kumar, M. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1743492 · Cited by 82
Eiró, N., Altadill, A., Salcedo, L. M. J., Rodríguez, M., González, L. O., Atienza, S., Bermúdez, S., Fernández‐García, B., Fresno-Forcelledo, M. F., Rodrigo, L., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12180 · Cited by 69
Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease
Tan-Garcia, A., Wai, L.-E., Zheng, D., Ceccarello, E., Jo, J., Banu, N., Khakpoor, A., Chia, A., Tham, C. Y. L., Tan, A. T., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.023 · Cited by 68
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
Wu, J., Wang, S., Zheng, B. J., Qiu, X., Wang, H., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669150 · Cited by 72
The interplay between the microbiome and the adaptive immune response in cancer development
Russo, E., Taddei, A., Ringressi, M. N., Ricci, F., & Amedei, A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16635082 · Cited by 68
Zhang, H., Liu, J., Lv, Y., Jiang, Y., Pan, J., Zhu, Y.-J., Huang, M., & Zhang, S.-K. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.021 · Cited by 68
Mechanistic understanding of β-cryptoxanthin and lycopene in cancer prevention in animal models
Lim, J. Y., & Wang, X. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158652 · Cited by 70
Publisher Correction: The gut–liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 70
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis
Silveira, M. A. D., Bilodeau, S., Greten, T. F., Wang, X. W., & Trinchieri, G. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.02.009 · Cited by 69
Liver Injury and the Activation of the Hepatic Myofibroblasts
Jiang, J. X., & Torok, N. J. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0019-6 · Cited by 70
Wang, Y., Tu, Q., Yan, W., Xiao, D., Zeng, Z., Ouyang, Y., Huang, L., Cai, J., Zeng, X., Chen, Y., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.090 · Cited by 67
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
NLRX1 acts as tumor suppressor by regulating TNF-α induced apoptosis and metabolism in cancer cells
Singh, K., Poteryakhina, A. V., Zheltukhin, A. O., Bhatelia, K., Prajapati, P., Sripada, L., Tomar, D., Singh, R. K., Singh, A. K., Chumakov, P. M., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.016 · Cited by 70
The Intestinal Microbiota in Chronic Liver Disease
Henao‐Mejia, J., Elinav, E., Thaiss, C. A., & Flavell, R. A. (2013) · Advances in immunology · doi:10.1016/b978-0-12-410524-9.00003-7 · Cited by 70
Degroote, H., Vandierendonck, A., Geerts, A. M., Vlierberghe, H. V., & Devisscher, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/7819520 · Cited by 67
Ji, G., Ma, L., Yao, H., Ma, S., Si, X., Wang, Y., Bao, X., Ma, L., Chen, F., Ma, C., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.004 · Cited by 65
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma
Shen, R. D., Ke, L., Li, Q., Dang, X., Shen, S., Shen, J., Li, S., Liang, L., Peng, B., Kuang, M., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10299-7 · Cited by 67
Probiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
Human Gut Microbiota in Health and Selected Cancers
Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413440 · Cited by 71
Chattopadhyay, I., Gundamaraju, R., Jha, N. K., Gupta, P. K., Dey, A., Mandal, C. C., & Ford, B. M. (2022) · Disease Markers · doi:10.1155/2022/2941248 · Cited by 67
Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma
Liang, B., Chen, R., Wang, T., Cao, L., Liu, Y., Yin, F., Zhu, M., Fan, X., Liang, Y., Zhang, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1245 · Cited by 64
STAT3 in hepatocellular carcinoma: new perspectives
Svinka, J., Mikulits, W., & Eferl, R. (2014) · Hepatic Oncology · doi:10.2217/hep.13.7 · Cited by 63
Liu, W.-T., Jing, Y.-Y., Gao, L., Li, R., Yang, X., Pan, X.-R., Yang, Y., Meng, Y., Hou, X.-J., Zhao, Q.-D., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0340-7 · Cited by 63
Deng, T., Li, J., He, B., Chen, B., Liu, F., Chen, Z., Zheng, J., Shi, Z., Zhang, T., Deng, L., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10279-3 · Cited by 64
Wang, Z., Yan, J., Lin, H., Hua, F., Wang, X., Liu, H., Lv, X., Yu, J., Mi, S., Wang, J., et al. (2013) · Hepatology · doi:10.1002/hep.26234 · Cited by 65
Yeh, D., Huang, L.-R., Chen, Y., Huang, C. F., & Chuang, T. (2016) · Journal of Immunology Research · doi:10.1155/2016/4368101 · Cited by 63
Zhang, Y., Zhao, F., Deng, Y., Zhao, Y., & Ren, H. (2015) · Journal of Proteome Research · doi:10.1021/pr5011263 · Cited by 62
Zhang, T., Zhang, S., Chen, J., Lin, Z., Deng, T., Xie, X., Deng, L., Li, X., Ma, J., Ding, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.751795 · Cited by 62
Non-viral causes of liver cancer: Does obesity led inflammation play a role?
Alzahrani, B., Iseli, T. J., & Hebbard, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.036 · Cited by 63
Miura, K., Ishioka, M., Minami, S., Horie, Y., Ohshima, S., Goto, T., & Ohnishi, H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.709048 · Cited by 61
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma
Sanduzzi‐Zamparelli, M., Rocco, A., Compare, D., & Nardone, G. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617705576 · Cited by 60
Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy
Tan-Garcia, A., Lai, F., Yeong, J. P.-S., Irac, S. E., Ng, P. Y., Msallam, R., Lim, J. C. T., Wai, L., Tham, C. Y. L., Choo, S. P., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.11.006 · Cited by 63
Mu, X., Pradère, J., Affò, S., Dapito, D. H., Friedman, R. A., Lefkowitch, J. H., & Schwabe, R. F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.11.039 · Cited by 64
Self-citationIntestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis
Schneider, K. M., Mohs, A., Kilic, K., Candels, L. S., Elfers, C., Bennek, E., Schneider, L. B., Heymann, F., Gaßler, N., Penders, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020308 · Cited by 61
Wu, R., Mei, X., Ye, Y., Xue, T., Wang, J.-S., Sun, W., Lin, C., Xue, R., Zhang, J., & Xu, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104454 · Cited by 61
Dutta, D., & Lim, S. H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00211-6 · Cited by 61
Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities
García‐Pras, E., Fernández‐Iglesias, A., Gracia‐Sancho, J., & Pérez‐del‐Pulgar, S. (2021) · Cancers · doi:10.3390/cancers14010048 · Cited by 62
Global research trends on the links between the gut microbiome and cancer: a visualization analysis
Zyoud, S. H., Al‐Jabi, S. W., Amer, R. A., Shakhshir, M. H., Shahwan, M. J., Jairoun, A. A., Akkawi, M., & Taha, A. A. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03293-y · Cited by 60
Agosti, P., Sabbà, C., & Mazzocca, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.11.026 · Cited by 59
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 62
Milestones in the pathogenesis and management of primary liver cancer
Nault, J., Cheng, A., Sangro, B., & Llovet, J. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.006 · Cited by 61
Rong, Y., Dong, Z., Hong, Z., Jin, Y., Zhang, W., Zhang, B., Mao, W., Kong, H., Wang, C., Yang, B., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.009 · Cited by 59
Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression
Noci, V. L., Bernardo, G., Bianchi, F., Tagliabue, E., Sommariva, M., & Sfondrini, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.732192 · Cited by 60
Liu, Y., Zhang, X., Chen, S., Wang, J., Yu, S., Li, Y., Xu, M. M., Aboubacar, H., Li, J., Shan, T., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0039 · Cited by 59
Koppe, C., Verheugd, P., Gautheron, J., Reisinger, F., Kreggenwinkel, K., Roderburg, C., Quagliata, L., Terracciano, L., Gaßler, N., Tolba, R. H., et al. (2016) · Hepatology · doi:10.1002/hep.28723 · Cited by 60
Toll like receptor 4 and hepatocellular carcinoma; A systematic review
Sepehri, Z., Kiani, Z., Kohan, F., Alavian, S. M., & Ghavami, S. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.04.025 · Cited by 61
Zheng, X., Liu, W., Xiang, J., Liu, P., Ke, M., Wang, B., Wu, R., & Lv, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21525 · Cited by 59
Filliol, A. A., & Schwabe, R. F. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1685539 · Cited by 60
Self-citationWhat’s new in NAFLD pathogenesis, biomarkers and treatment?
Byrne, C. D., & Targher, G. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0239-2 · Cited by 58
Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy
Luo, W., Guo, S., Zhou, Y., Zhao, J., Wang, M., Sang, L.-X., Chang, B., & Wang, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.873160 · Cited by 62
Takahashi, Y., Dungubat, E., Kusano, H., & Fukusato, T. (2023) · Biomedicines · doi:10.3390/biomedicines11102761 · Cited by 53
Song, I. J., Yang, Y. M., Inokuchi‐Shimizu, S., Roh, Y. S., Yang, L., & Seki, E. (2017) · International Journal of Cancer · doi:10.1002/ijc.31029 · Cited by 58
Saber, S., Mahmoud, A. A. A., Goda, R. M., Helal, N. S., El-Ahwany, E. G., & Abdel-Ghany, R. H. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.05.036 · Cited by 58
Grgurević, I., Božin, T., Mikuš, M., Kukla, M., & O’Beirne, J. P. (2021) · Cancers · doi:10.3390/cancers13225844 · Cited by 58
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis
Baechler, S., Factor, V. M., Rosa, I. D., Ravji, A., Becker, D., Khiati, S., Jenkins, L. M. M., Lang, M., Sourbier, C., Michaels, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07922-3 · Cited by 62
Cui, Y., Qi, S., Zhang, W., Mao, J., Tang, R., Wang, C., Liu, J., Luo, X., & Wang, H. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz088 · Cited by 58
Giannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., Iavarone, M. A., Lai, Q., Sandri, G. B. L., Melandro, F., Morisco, F., et al. (2019) · Cancers · doi:10.3390/cancers11111689 · Cited by 57
Hepatoprotective effects of silymarin coated gold nanoparticles in experimental cholestasis
Clichici, S. V., David, L., Moldovan, B. E., Bâldea, I., Olteanu, D. E., Filip, M., Nagy, A. L., Luca, V., Crivii, C. B., Mircea, P. A., et al. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111117 · Cited by 57
Metadata
- Authors
- Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., Lefkowitch, J. H., Bower, M., Friedman, R., Sartor, R. B., Rabadan, R., & Schwabe, R. F.
- Affiliations
- Columbia University (US)
- Samsung Medical Center (KR)
- Hospital Clínic de Barcelona (ES)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Schwabe, Robert F.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 21
- Issue
- 4
- Pages
- 504-516
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3332000
- OpenAlex
- W2085153086
- Cited by
- 1,346
- References
- 50
- Citations by year
- 2026: 63 · 2025: 103 · 2024: 106 · 2023: 111 · 2022: 149 · 2021: 133 · 2020: 129 · 2019: 104 · 2018: 93 · 2017: 94 · 2016: 79 · 2015: 64 · 2014: 48 · 2013: 51 · 2012: 16
- FWCI
- 36.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 472 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (1F31 DK091980-01, P40RR018603, R01AA020211, R01DK076920, U54CA163111)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- hepatocellular carcinoma, gut microbiota, TLR4, gut-liver axis, chronic liver injury, hepatocarcinogenesis, bacterial translocation, epiregulin, apoptosis, HCC prevention, liver fibrosis, liver inflammation
- MeSH terms
- Animals, Epidermal Growth Factor, Humans, Intestines, Liver Diseases, Liver Neoplasms, Experimental, Mice, Inbred C57BL, Tumor Cells, Cultured, Apoptosis, Bacterial Translocation, Cell Proliferation, Toll-Like Receptor 4, Mice, Epiregulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
